Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

January 15, 2024

Study Completion Date

March 25, 2025

Conditions
Gastric CancerGastroesophageal Junction CancerHER2-positive Gastric Cancer
Interventions
BIOLOGICAL

margetuximab

margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle

BIOLOGICAL

Retifanlimab

Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.

BIOLOGICAL

Tebotelimab

Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.

BIOLOGICAL

Trastuzumab

Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle

OTHER

Chemotherapy

"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."

Trial Locations (73)

110

Taipei Medical University Hospital, Taipei City

204

Chang Gung Memorial Hospital, Keelung, Keelung

14068

Hallym University Sacred Heart Hospital, Anyang-si

20132

Ospedale San Raffaele, Milan

22031

Virginia Cancer Specialists, Fairfax

32224

Mayo Clinic - Jacksonville, Jacksonville

33705

Florida Cancer Specialists North, St. Petersburg

33901

Florida Cancer Specialists South, Fort Myers

34474

Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala, Ocala

37203

Sarah Cannon Research Institute, Nashville

48202

Henry Ford Health System, Detroit

49503

Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion, Grand Rapids

53792

University of Wisconsin, Madison

55905

Mayo Clinic - Rochester, Rochester

56126

Azienda Ospedaliero-Universitaria Pisana, Pisa

60076

Edward H. Kaplan MD & Associates, Skokie

60488

Institute of Clinical Cancer Research Krankenhaus Nordwest (IKF), Frankfurt

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

68506

Nebraska Heme Onc, Lincoln

73104

Stephenson Cancer Center at OUHSC, Oklahoma City

73657

Liuying Chi MeiMedical Hospital, Tainan City

77030

Oncology Consultants, Houston

83301

Kaohsiung Chang Gung MemorialHospital, Kaohsiung City

84106

Utah Cancer Specialists, Salt Lake City

85259

Mayo Clinic - Scottsdale, Scottsdale

87131

The University of New Mexico Comprehensive Cancer Center, Albuquerque

90033

Norris Comprehensive Cancer Center (USC), Los Angeles

90404

UCLA School of Medicine, Santa Monica

91010

City of Hope Comprehensive Cancer Center - Duarte, Duarte

93901

Salinas Memorial, Salinas

96814

Kaiser Permanente, Honolulu

98104

Swedish Cancer Institute, Seattle

100142

Beijing Cancer Hospital, Beijing

110042

Liaoning cancer hospital, Shenyang

119074

National University Hospital (Cancer Institute) -Singapore, Singapore

130000

Jilin Cancer Hospital (Second People's Hospital Of Jilin Province), Changchun

150081

Affiliated Tumor Hospital of Harbin Medical University- the 3rd Affiliated Hospital of Harbin, Harbin

169610

National Cancer Center Singapore, Singapore

200433

Zhongshan Hospital Fudan University, Shanghai

210000

Nanjing University Medical School; Nanjing Drug Tower, Nanjing

230022

The First Affiliated Hospital of Anhui Medical University, Hefei

230031

Anhui Provincial Cancer Hospital, Hefei

250013

Jinan Center Hospital, Jinan

310016

SIR RUN RUN SHAW Hospital, Zhejiang University school of medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

350005

Fujian Medical University - Fujian Provincial Cancer Hospital (Fujian Provincial Tumor Hospital), Fuzhou

430022

Wuhan Union Hospital, Wuhan

450008

Henan Cancer Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhenzhou

06511

Yale University, New Haven

02114

Massachusetts General Hospital Cancer Center, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

050000

Hebei cancer hospital (The Fourth Affiliate), Shijiazhuang

Unknown

Haematologisch-Onkologische Praxis Eppendorf, Hamburg

Universitätsmedizin Mainz, Mainz

Kliniken Maria Hilf GmbH, Mönchengladbach

Istituto Europeo Di Oncologia, Milan

CHA bundang, Gyeonggi-do

Inje University Haeundae Paik Hospital, Haeundae

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Korea University Guro, Seoul

Korea University, Anam Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Yonsei University College of Medicine (Severance Hospital), Seoul

Catholic University of Korea St. Vincent Hospital, Suwon

National Taiwan University, Taipei

Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital, Cambridge

The Christie Hospital NHS Foundation Trust, Manchester

20-081

SPSK nr 1 in Lublin, Lublin

35-922

Centrum Medyczne MrukMed, Rzeszów

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

lead

MacroGenics

INDUSTRY

NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | Biotech Hunter | Biotech Hunter